October 1st 2020
By Skylar Jeremias
Centus’ Equidacent became Europe’s fourth bevacizumab biosimilar to receive marketing authorization.
September 29th 2020
California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.
By Deana Ferreri, PhD
Germany could eke out more gains from biosimilars on top of its already impressive savings, investigators write.
September 28th 2020
Trial results demonstrated that Innovent Biologics’ bevacizumab biosimilar was effective in combination therapy with a PD-1 inhibitor in patients with hepatocellular carcinoma.
By Tony Hagen
Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.
A secretive biosimilars company notches yet another co-licensing deal but withholds full details.
September 25th 2020
A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.
September 22nd 2020
Biosimilars from Samsung Bioepis have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists.
September 21st 2020
Breast cancer specialist Hope S. Rugo, MD, FASCO, an advisory board member for The Center for Biosimilars®, has been at the forefront of groundbreaking oncology advancements.
Lotus and CKD Pharmaceutical intend to be among the first to bring a darbepoetin alpha biosimilar to Southeast Asia.
